GLP-1 drugs before anesthesia
Should GLP-1 receptor agonists be continued or withheld before anesthesia? Compare residual gastric-content studies with actual aspiration outcomes, and distinguish elective surgery from endoscopy.
Published studies
Open in feedRecent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.
Showing 35 of 87 · Review
Recent evidence · past year
-
Preoperative GLP-1 Receptor Agonist Use and Postoperative Outcomes Across Plastic and Reconstructive Surgery: A Systematic Review and Meta-Analysis.
AI summary of the abstract, unverified
- Systematic review and meta-analysis of 13 comparative studies including 17,426 adults undergoing plastic and reconstructive surgery, 8,745 of whom used GLP-1 RAs.
- Compared preoperative GLP-1 receptor agonist use with no use, pooling risk ratios with random-effects models.
- No association was found with wound dehiscence, surgical site infection, seroma, haematoma or venous thromboembolism, but hypertrophic scarring was higher (RR 1.55; 95% CI 1.01-2.38).
- The authors judge the evidence very low certainty and hypothesis-generating, favouring individualised perioperative management over routine restriction of GLP-1 RAs.
Original abstract (PubMed)
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for pre-operative weight loss before body-contouring procedures, yet their effects on wound healing are poorly characterised and evidence on post-operative complications is conflicting. METHODS: We searched PubMed, Embase, Cochrane, ClinicalTrials.gov and the WHO ICTRP (to May 2026) for comparative studies of pre-operative GLP-1 RA use versus no use in adults undergoing plastic and reconstructive surgery. Risk ratios (RR) were pooled using random-effects models (REML; Hartung-Knapp-Sidik-Jonkman confidence intervals [CI]); pre-specified population subgroups were compared. Analyses used R (version 4.3). RESULTS: In total, 13 studies (n = 17,426; 8,745 GLP-1 RA users) were included. Pre-operative GLP-1 RA use was not associated with wound dehiscence (RR 1.05; 95% CI 0.73-1.52), surgical site infection (RR 0.83; 0.60-1.16), seroma (RR 1.12; 0.67-1.87), haematoma (RR 1.13; 0.67-1.90) or venous thromboembolism (RR 0.61; 0.34-1.08). Hypertrophic scarring was increased (RR 1.55; 95% CI 1.01-2.38). Tests for differences between the general-population, post-bariatric and reconstructive subgroups were non-significant for all outcomes except surgical site infection (P < .001), which showed lower rates in the reconstructive subgroup. CONCLUSION: In adults undergoing plastic and reconstructive surgery, pre-operative GLP-1 RA use was not associated with an overall increase in post-operative complications, apart from a modest increase in hypertrophic scarring, and population subgroups did not differ except for surgical site infection. Given the very low certainty of evidence, these findings are hypothesis-generating and support individualised perioperative management rather than routine restriction of GLP-1 RAs. LEVEL OF EVIDENCE: Level III (risk/prognostic study).
-
What's Coming Up Next? The Physiology of Gastroparesis and GLP-1 Agonists.
AI summary of the abstract, unverified
- This is a narrative review of GLP-1 physiology and the upper gastrointestinal effects of GLP-1 receptor agonists, with no original patient data reported in the abstract.
- It covers approved peptide, nonpeptide, and combined GLP-1/GIP agonists, and the nausea, vomiting, and delayed gastric emptying they can cause.
- The authors describe a theoretical risk of pulmonary aspiration from retained gastric contents in patients undergoing anesthesia for endoscopy or surgery.
- Management options named include diet changes, antiemetics, and prokinetic treatments, and newer agents acting through GIP, glucagon, or other pathways are still in testing.
Original abstract (PubMed)
Glucagon-like peptide-1 (GLP-1) is an incretin to regulate glycemia, activates peripheral and central neural pathways to control appetite, and inhibits upper gut transit to reduce food intake. Peptide and nonpeptide GLP-1 receptor agonists (GLP-1RAs), as well as a combined GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), agonist are approved for type 2 diabetes, weight reduction, and other indications. GLP-1RA therapy can be complicated by upper gastrointestinal (GI) symptoms, including nausea and vomiting. Delayed gastric emptying secondary to GLP-1RAs may be influenced by drug pharmacokinetics, associated neuropathy, and development of tachyphylaxis with repeated dosing. A theoretical risk of pulmonary aspiration from retained gastric contents is concerning for patients undergoing anesthesia before endoscopy or surgery. Managing upper GI complications of GLP-1RA therapy includes diet modifications, antiemetic medications, and treatments that stimulate gastric emptying. Newer agents in testing include nonpeptide GLP-1RAs and GLP-1RAs acting in concert with GIP, glucagon, or other receptor-mediated pathways.
-
Surgical Management of Hidradenitis Suppurativa: Current Evidence and Practical Guidance.
AI summary of the abstract, unverified
- This review summarizes surgical management of hidradenitis suppurativa, a chronic inflammatory disease that can progress to tunnels, fibrosis, and scarring.
- It covers when to refer for surgery, how lesion architecture and anatomic site guide procedure choice, and how perioperative biologics can be combined with operative treatment.
- Deroofing is described as most suitable for localized tunnels, while wide excision offers more durable local control for diffuse or deeply interconnected disease.
- The authors emphasize individualized procedure selection, integration with medical therapy, and standardized outcome reporting, and also discuss ultrasound staging and GLP-1 receptor agonists as adjuncts.
Original abstract (PubMed)
Hidradenitis suppurativa is a chronic inflammatory skin disease that frequently progresses from recurrent nodules and abscesses to tunnels, fibrosis, scarring, and substantial quality-of-life impairment. Medical therapy is essential for controlling inflammatory activity, but surgery remains central to the management of structurally irreversible disease. This review summarizes the role of surgery within contemporary hidradenitis suppurativa care, with attention to when surgical referral should occur, how lesion architecture and anatomic site influence procedure selection, and how perioperative biologic therapy can be integrated with operative treatment. Tissue-sparing approaches such as deroofing are most appropriate for localized tunnels, whereas wide excision offers more durable local control for diffuse or deeply interconnected disease. Outcomes are shaped not only by procedure choice, but also by reconstruction strategy, postoperative wound care, anatomic constraints, and access to coordinated multidisciplinary care. The review also discusses evolving areas of interest, including earlier intervention, ultrasound for disease staging and presurgical mapping, and glucagon-like peptide-1 receptor agonists as adjunctive therapy in selected patients with obesity or metabolic comorbidity. Overall, optimal hidradenitis suppurativa surgery depends on individualized procedure selection, integration with medical therapy, and standardized outcome reporting to improve long-term patient care.
-
Beyond Weight Loss: A Scoping Review and Thematic Analysis of GLP-1 Receptor Agonists Across the Neurosurgical Landscape.
AI summary of the abstract, unverified
- Scoping review (PRISMA-ScR) of 48 included studies from 1,342 screened, mostly US-based and retrospective (43/48).
- Included studies examined GLP-1 receptor agonist exposure in adults with spinal, intracranial, or cerebrovascular disease, grouped into three themes.
- Spinal fusion studies repeatedly linked perioperative exposure to lower pseudarthrosis, though some reported more postoperative complications; IIH studies linked it to lower papilledema and shunt placement.
- The authors judge benefit signals most consistent in spinal fusion and IIH, but adverse effects and database overlap limit causal inference, and they call for prospective trials.
Original abstract (PubMed)
BACKGROUND: GLP-1 receptor agonists (GLP-1RAs) are increasingly used for diabetes and obesity. Literature spans spinal fusion, idiopathic intracranial hypertension (IIH), and cerebrovascular disease, but has not been systematically mapped. We aimed to map literature on GLP-1RA exposure in neurosurgical landscapes by characterizing study design, drug class, disease-specific outcomes, and safety considerations. METHODS: This scoping review was conducted per the PRISMA-ScR guideline. Eligible studies reported GLP-1RA exposure in adults with spinal, intracranial, or cerebrovascular disease, recording clinical, perioperative, or imaging outcomes. Two reviewers screened independently with third-reviewer adjudication. Extracted variables included country, design, agent, timing, indication, neurosurgical and metabolic outcomes, and adverse events. RESULTS: Of 1342, 48 were included, predominantly from the United States (US) (34/48, 71%). Most were retrospective (43/48, 90%); 31/48 (65%) used propensity score matching; 5/48 (10%) were randomized. Three themes dominated: spinal fusion (24/48, 50%), IIH and cerebrospinal fluid (CSF) dynamics (14/48, 29%), and cerebrovascular and neurointerventional disease (10/48, 21%). In spinal fusion, perioperative GLP-1RA exposure was repeatedly associated with lower pseudarthrosis, although some studies reported increased postoperative complications. In IIH, GLP-1RAs were associated with lower papilledema, fewer CSF leaks, reduced acetazolamide requirement, and lower shunt placement. Cerebrovascular reports described lower intracerebral hemorrhage, subarachnoid hemorrhage, and post-stroke mortality, mostly in observational studies. CONCLUSIONS: GLP-1RA neurosurgical literature is dominated by US-based retrospective, propensity-matched analyses. Benefit signals are most consistent in spinal fusion and IIH, but perioperative adverse effects and overlap among database cohorts limit causal interpretation. Adequately powered prospective trials with standardized endpoints are needed to confirm results.
-
Urological manifestations in obesity.
AI summary of the abstract, unverified
- This narrative review summarizes recent evidence on obesity's effects across urology, including cancer, stone disease, incontinence, male reproductive health, kidney disease, and pediatric urology.
- It discusses SGLT2 inhibitors and GLP-1 receptor agonists for stone and infection risk, and weight loss or bariatric surgery for overactive bladder and stress incontinence.
- Findings are qualitative: obesity is described as offering a paradoxical survival benefit in renal cell carcinoma but driving aggressive prostate cancer, with no effect sizes given.
- The authors conclude that obesity's urological effects are heterogeneous and that weight loss and GLP-1 receptor agonists may help optimize and treat these conditions.
Original abstract (PubMed)
PURPOSE OF REVIEW: The global prevalence of obesity continues to rise, with effects ranging across urology. This review summarizes recent evidence on obesity and its impact on various urological conditions, including malignancy, infections, stone disease, functional urology and male reproductive health, chronic kidney disease, and pediatric urology, to guide comprehensive management in this population. RECENT FINDINGS: Obesity has a paradoxical survival benefit in patients with renal cell carcinoma, while its impact drives aggressive prostate cancer. Obesity increases kidney stone risk, with sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists showing divergent effects on lithogenesis and urinary tract infections. It is a modifiable risk factor for overactive bladder and stress urinary incontinence, both of which improve with weight loss/ bariatric surgery. Robotic surgery mitigates obesity-related perioperative risk. Hypogonadism secondary to obesity is a major reversible cause of male infertility. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) reverse metabolic hypogonadism and helps in slowing chronic kidney progression. Maternal and childhood obesity may impair testicular descent and can also increase the risk of nocturnal enuresis. SUMMARY: Obesity's urological effects are heterogeneous, paradoxical from pediatric to adults, mediated by insulin resistance, chronic inflammation, and hormonal dysregulation. Weight loss and the use of GLP-1 RA may offer a unique strategy for optimizing and treating urological conditions.
-
Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies.
AI summary of the abstract, unverified
- This is a narrative review of safety evidence for GLP-1 receptor agonists used in type 2 diabetes and obesity.
- Most safety evidence comes from pharmacovigilance databases, retrospective observational studies, and secondary trial analyses, which cannot establish causality.
- Gastrointestinal intolerance, modest heart rate increases, and gallbladder or biliary disease are the most consistently supported adverse effects, while pancreatitis risk remains debated.
- The authors judge the overall benefit-risk profile favorable and regard most other emerging concerns as hypothesis-generating rather than established toxicities.
Original abstract (PubMed)
PURPOSE OF REVIEW: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent one of the most significant therapeutic advances in the management of type 2 diabetes and obesity. As their indications have expanded to include cardiovascular and kidney disease, safety concerns involving multiple organ systems have received increasing attention. This narrative review examines the spectrum of adverse effects linked to GLP-1RAs and provides a clinically relevant platform for assessing their safe prescription. RECENT FINDINGS: Gastrointestinal intolerance, modest increases in heart rate, and a modest but reproducible increase in the risk of gallbladder and biliary disease represent the most consistently supported adverse effects of GLP-1RAs. A risk of pancreatitis is also considered to exist, although some studies have challenged this association. Conversely, correlations with neuropsychiatric and dermatological disorders, diabetic retinopathy, nonarteritic anterior ischemic optic neuropathy, perioperative aspiration, sexual and reproductive disturbances, sarcopenia, and malignancy remain controversial. Most available evidence derives from pharmacovigilance databases, retrospective observational studies, and secondary analyses of randomized trials, which are limited by reporting bias, residual confounding, and inability to establish causality. Heterogeneity in study design, statistical methodology, outcome definitions, and patient populations further complicates interpretation. Although several proposed adverse effects have biologically plausible mechanisms, prospective clinical validation remains limited. Notably, recent regulatory decisions, including the Food and Drug Administration (FDA)'s removal of the suicidality warning from GLP-1RA prescribing information, reflect the evolving nature of these safety assessments. The overall benefit-risk profile of GLP-1RAs is favorable. Most emerging safety concerns should currently be regarded as hypothesis-generating signals rather than established toxicities. Individualized risk assessment and appropriate clinical monitoring remain important as ongoing and future prospective studies further define the long-term safety of this rapidly expanding therapeutic class.
-
Do Glucagon-Like Peptide-1 Receptor Agonists Sabotage Fat Grafts?: A Scoping Review of Glucagon-Like Peptide-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.
AI summary of the abstract, unverified
- This scoping review (PRISMA-ScR) synthesizes preclinical and clinical evidence on semaglutide, liraglutide, tirzepatide, and retatrutide effects on adipocytes and fat graft biology.
- The exposure is GLP-1 receptor agonist use, and the review maps its effects on adipocyte metabolism, adipose-derived stem cells, and revascularization onto models of fat graft take.
- The authors identify several potential interference points, including adipocyte browning, enhanced lipolysis, shifted stem cell differentiation, and altered inflammatory and angiogenic signaling, but no study has directly measured fat graft outcomes in patients on incretin therapies.
- The authors propose a research framework and preliminary perioperative considerations, which they explicitly label as hypothesis-generating rather than evidence-based guidance.
Original abstract (PubMed)
The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight management has created an unprecedented overlap with aesthetic surgery. Millions of patients experiencing GLP-1-mediated weight loss now present with facial volume depletion, soft tissue deflation, and contour irregularities; conditions for which autologous fat grafting remains the gold-standard solution. However, the fundamental biology of GLP-1 receptor agonism may be inherently antagonistic to the mechanisms upon which fat graft survival depends. This scoping review, conducted in accordance with the PRISMA extension for Scoping Reviews (PRISMA-ScR), synthesizes current preclinical and clinical evidence on the effects of semaglutide, liraglutide, tirzepatide, and the emerging triple agonist retatrutide on adipocyte metabolism, adipose-derived stem cell (ASC) function, and tissue revascularization, and maps these effects onto established models of fat graft take. We identify multiple potential interference points, including GLP-1-mediated adipocyte browning and thermogenic activation with upregulation of uncoupling protein 1 (UCP1) and mitochondrial uncoupling, enhanced lipolysis through adipose triglyceride lipase and hormone-sensitive lipase (HSL) upregulation, suppression of white adipogenic differentiation in ASCs with preferential commitment toward thermogenic beige lineages, and modulation of inflammatory and angiogenic signaling during the critical revascularization window. The growing off-label use of retatrutide in bodybuilding communities introduces additional concerns through glucagon receptor-mediated lipolysis and thermogenesis. Despite the strong mechanistic rationale, no clinical or preclinical studies have directly examined fat graft outcomes in patients receiving incretin-based therapies. We propose a framework for future investigation and offer preliminary, mechanism-based clinical considerations regarding perioperative GLP-1 RA management in fat transfer patients. These recommendations should be understood as hypothesis-generating rather than evidence-based guidelines. Level of Evidence: 1 (Therapeutic) For image description, please refer to the figure legend and surrounding text.
-
Thyroid Disease in the Era of Obesity and Glucagon-Like-Peptide-1 Agonists.
AI summary of the abstract, unverified
- The article addresses the relationship between thyroid disease and obesity, which the abstract describes as complex and bidirectional.
- It notes that both hypothyroidism and hyperthyroidism can influence body weight, and that body mass index is closely associated with thyroid dysfunction.
- It highlights a rise in thyroid cancer incidence alongside obesity prevalence over the past decade, and notes that the link between emerging weight-loss therapies and thyroid malignancy is still under investigation.
- It also covers perioperative and surgical considerations for patients undergoing thyroidectomy.
Original abstract (PubMed)
The thyroid gland plays a critical role in regulating metabolism. Dysfunctions in the thyroid gland are closely associated with alterations in body mass index. The relationship between thyroid disease and obesity is complex and bidirectional with hypothyroidism and hyperthyroidism influencing body weight. In the last decade, there has been an increase in the incidence of thyroid cancer as well as the prevalence of obesity. Emerging weight loss therapies and their potential association with thyroid malignancy remains an active area of investigation. Additionally, important perioperative and surgical considerations must be addressed in patients undergoing thyroidectomy.
-
The gut-pancreas axis in chronic pancreatitis: Microbiota-endogenous GLP-1 interactions and candidate repair pathways.
AI summary of the abstract, unverified
- This is a narrative review combining chronic pancreatitis clinical data with cell, rodent, and non-CP human mechanistic studies, with no pooled quantitative analysis.
- It examines how intestinal barrier disruption raises lipopolysaccharide exposure and engages TLR4 signaling, and how microbial metabolites influence enteroendocrine L-cell GLP-1 secretion.
- Human CP studies of GLP-1 show heterogeneous responses, and no CP trial has yet linked microbiota-driven GLP-1 changes to disease progression.
- The authors propose a testable microbiota-metabolite-endogenous GLP-1 framework for CP, with causal direction and clinical relevance still requiring longitudinal validation.
Original abstract (PubMed)
Chronic pancreatitis (CP) is a progressive fibroinflammatory disorder with limited disease-modifying options. Human CP studies report gut microbial and intestinal-barrier alterations, predominantly in cross-sectional cohorts. This review integrates CP-specific clinical and experimental observations with mechanistic evidence from cell, rodent, and non-CP human studies. Barrier disruption can increase lipopolysaccharide exposure and engage Toll-like receptor 4-associated inflammatory and fibrogenic signaling, whereas microbial and host-derived metabolites regulate enteroendocrine L-cell secretion through defined receptor-mediated and metabolic pathways. Human glucagon-like peptide-1 (GLP-1) studies in CP show heterogeneous responses, while CP trials have not yet connected microbiota-driven GLP-1 changes to disease progression. Evidence for direct pancreatic GLP-1 receptor (GLP-1R) signaling is strongest in β cells; reported immune, stellate-cell, and exocrine effects derive largely from preclinical or pharmacological studies and should not be equated with physiological endogenous GLP-1 exposure. CP-specific animal studies reported attenuated fibrosis or improved barrier and immune endpoints after microbiota-directed interventions, whereas limited human synbiotic trials reported improvements in selected gastrointestinal or perioperative outcomes but did not assess endogenous GLP-1, microbiome engraftment, pancreatic fibrosis, or disease progression. Together, these findings support a biologically coherent and testable microbiota-metabolite-endogenous GLP-1 framework for CP, with causal direction and clinical relevance requiring longitudinal validation. Translation requires microbiome-stratified CP trials incorporating functional microbiome and metabolite profiling; basal and meal-stimulated measurements of active and total GLP-1, together with peptide YY; prespecified clinical outcomes; mediation and treatment-by-biomarker analyses; and long-term safety assessment.
-
Glucagon-like peptide-1 receptor agonists and aesthetic surgery: perioperative safety, timing, durability and body composition.
AI summary of the abstract, unverified
- This mini-review synthesizes existing evidence on GLP-1 receptor agonists and dual incretin agonists in patients seeking aesthetic and reconstructive surgery.
- It covers perioperative risks, including delayed gastric emptying with possible aspiration, GI effects during dose escalation, lean mass loss, and weight regain after discontinuation.
- It reviews shifting anesthesia society guidance, from blanket preoperative withholding toward individualized risk stratification, and emerging body contouring outcome data in these users.
- The authors propose a framework for timing elective procedures around drug initiation, escalation, and maintenance, anchored in weight stability and symptom burden, plus a multidisciplinary endocrine-surgical-anesthetic algorithm.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin agonists have transformed the management of obesity and type 2 diabetes and are rapidly reshaping the population seeking aesthetic surgery. By producing double-digit percentage weight loss, these agents expand eligibility for elective procedures while generating new patterns of skin redundancy, soft-tissue laxity, and facial volume depletion that drive demand for body contouring and facial rejuvenation. At the same time, incretin therapy introduces distinct perioperative considerations: delayed gastric emptying with possible pulmonary aspiration in symptomatic patients, gastrointestinal adverse effects that peak during dose escalation, loss of lean mass with rapid weight reduction, nutritional inadequacy during profound appetite suppression, and frequent weight regain after drug discontinuation, which threatens the durability of surgical results. This mini-review synthesizes current evidence on the mechanisms of GLP-1 RAs relevant to the reconstructive surgical patient, summarizes the evolving guidance from anesthesia societies, moving from blanket preoperative withholding to individualized risk stratification, reviews emerging outcome data on body contouring in GLP-1 RA users, and discusses body composition, sarcopenia risk, and nutritional optimization. We propose a pragmatic framework, anchored in weight stability and symptom burden, for timing elective aesthetic procedures relative to GLP-1 RA initiation, escalation, and maintenance, along with a multidisciplinary perioperative algorithm that links the endocrinologist, plastic surgeon, and anesthesiologist. As incretin-based pharmacotherapy expands globally, coordinated endocrine-surgical-anesthetic care will be essential to maximize safety, functional recovery, and patient satisfaction in the GLP-1 era.
-
Perioperative management of GLP-1 receptor agonists and SGLT2 inhibitors: An updated review for anesthesiologists.
AI summary of the abstract, unverified
- This is a narrative review that synthesizes evolving evidence and international guidance on perioperative management of GLP-1 receptor agonists and SGLT2 inhibitors.
- GLP-1 receptor agonists slow gastric emptying, raising aspiration concern, but recent large-scale data reportedly show no increase in clinically significant aspiration under modern anesthetic practice.
- For GLP-1 receptor agonists, the review supports an individualized, risk-based approach with targeted mitigation for higher-risk patients rather than routine cessation.
- Perioperative guidance for SGLT2 inhibitors has converged toward preoperative discontinuation to reduce euglycemic diabetic ketoacidosis risk, and the authors emphasize anesthesiologists coordinating care that balances metabolic safety with cardiovascular and renal benefit.
Original abstract (PubMed)
The widespread adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose linked transporter-2 (SGLT2) inhibitors have substantially improved glycemic control and cardiometabolic outcomes in patients with diabetes and related conditions. However, their increasing perioperative use has introduced important safety considerations for anesthesiologists. GLP-1RAs are associated with delayed gastric emptying, raising concerns regarding aspiration risk, while SGLT2 inhibitors have been linked to euglycemic diabetic ketoacidosis (EDKA), particularly in the context of surgical stress and perioperative fasting. This review synthesizes evolving evidence and international guidance to inform contemporary perioperative management of these agents. For GLP-1RAs, early recommendations advocating routine preoperative cessation have been increasingly challenged by recent large-scale outcome data demonstrating no increase in clinically significant aspiration under modern anesthetic practice, supporting an individualized, risk-based approach with targeted mitigation strategies for higher-risk patients. In contrast, perioperative guidance for SGLT2 inhibitors has converged toward preoperative discontinuation to minimize EDKA risk. The review highlights the central role of anesthesiologists in coordinating multidisciplinary, patient-centered care that balances metabolic safety with preservation of established cardiovascular and renal benefits.
-
Perioperative management of patients taking GLP-1 receptor agonists: A comparative review of international clinical guidelines.
AI summary of the abstract, unverified
- This systematic review appraised five perioperative GLP-1 receptor agonist guidelines published 2023 to 2026 using the AGREE-REX framework and reviewed their underlying primary studies.
- The review compared how the guidelines handle continuing these drugs before anesthesia, fasting modification, symptom-based risk stratification, and gastric ultrasound.
- Four of five guidelines recommend continuing the drug with structured fasting modification, replacing the 2023 ASA cessation policy, though fasting protocols still differ substantially.
- The authors conclude that guidelines share a direction but remain contested in operational details, and that prospective data on aspiration and glycemic events are urgently needed.
Original abstract (PubMed)
GLP-1 receptor agonists (GLP-1 RAs) are now routinely encountered in preoperative assessment. Their effect on gastric emptying raises concern about pulmonary aspiration risk during anesthesia. Five major professional bodies have published perioperative guidance since 2023, reaching divergent conclusions on four clinically important questions. A systematic search of PubMed, MEDLINE, Embase, professional society websites, and grey literature was conducted for perioperative GLP-1 RA guidelines published between January 2023 and March 2026. Five documents met eligibility criteria. Each was independently appraised by two reviewers using the AGREE-REX framework, and primary studies underpinning the guidelines were reviewed for four pre-specified clinical questions. Four of five guidelines now recommend drug continuation with structured fasting modification, superseding the 2023 American Society of Anesthesiologists (ASA) cessation policy. Fasting protocols diverge substantially: SPAQI 2025 uniquely distinguishes high-calorie from low-calorie liquids. Three of five documents explicitly state that absence of gastrointestinal symptoms cannot be relied upon for risk stratification. All five guidelines endorse gastric ultrasound but none define validated decision thresholds. AGREE-REX appraisal identified the Anesthetists of Great Britain and Ireland (AAGBI)/Royal College of Anesthetists (RCoA) 2025 statement as having the broadest multidisciplinary representation and the most transparent process; Society for Perioperative Assessment and Quality Improvement (SPAQI) 2025 had the most rigorous evidence base but the most complex implementation requirements. Endocrinologist and obesity medicine representation is absent from most authoring groups, and the recommendations reflect this. International guidelines share a direction, to continue with modified fasting, but the operational details remain contested. The clinical risks of incomplete gastric emptying, hypoglycemia in insulin-dependent patients, and the absence of validated gastric ultrasound decision thresholds are not yet adequately reflected in most guidance. Prospective outcome data capturing aspiration events and glycemic complications remain urgently needed.
-
Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
AI summary of the abstract, unverified
- Narrative expert review pooling RCTs, observational studies, meta-analyses, and pharmacovigilance data on GI adverse effects of GLP-1 and dual GIP/GLP-1 receptor agonists.
- Nausea, vomiting, diarrhea, and constipation are described as class effects in about 30%-50% of patients, mostly during initiation and dose escalation, and usually mild to moderate.
- Randomized data show no class-level excess acute pancreatitis risk, while cholelithiasis is a probable class association that is largely mediated by weight loss.
- The authors conclude GI events are predictable and manageable, and pipeline agents (retatrutide, survodutide, cagrilintide-semaglutide) show a similar profile, though evidence is limited.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists have transformed the management of type 2 diabetes and obesity. Gastrointestinal (GI) adverse events are the most common limitation of these therapies and a leading cause of discontinuation. METHODS: This narrative expert review synthesizes evidence from randomized controlled trials, observational studies, meta-analyses, and pharmacovigilance data to characterize the incidence, mechanisms, and clinical implications of GI adverse effects across approved agents and late-stage pipeline therapies. RESULTS: Nausea, vomiting, diarrhea, and constipation are established class effects, occurring in approximately 30%-50% of patients, typically during initiation and dose escalation. These events are generally mild to moderate and manageable with dose titration and dietary modification. Mechanisms include delayed gastric emptying, central activation of emetic pathways, altered intestinal motility, and physiologic effects of rapid weight loss itself. Randomized trial data are reassuring for acute pancreatitis, with no class-level excess risk demonstrated; pharmacovigilance signals are most plausibly explained by diagnostic misclassification rather than true causal risk. Cholelithiasis shows a probable class-level association, substantially mediated by weight loss rather than direct receptor signaling. Peri-procedural data show increased residual gastric volume without confirmed aspiration events. Preliminary data on late-stage pipeline agents (retatrutide, survodutide, and cagrilintide-semaglutide) suggest a similar GI adverse event profile to approved agents, though evidence remains largely limited. CONCLUSION: GI adverse events with GLP-1-based therapies are predictable and manageable. A proactive, patient-centered approach is essential to optimize adherence, safety, and clinical outcomes as newer agents expand the therapeutic landscape.
-
GLP-1 agonists before endoscopy: separating fact from fiction.
AI summary of the abstract, unverified
- This narrative review summarizes the physiology of GLP-1 agonist-delayed gastric emptying and recent literature on residual gastric volume before sedated endoscopy.
- The review compares holding the GLP-1 agonist dose with continuing it alongside 24 hours of clear liquids as preventive strategies.
- Both approaches are described as effective, with a trend favoring continuation plus clear liquids, and point-of-care ultrasound is described as highly accurate for detecting residual gastric volume in experienced hands.
- The authors conclude that recent studies have considerably improved understanding of the pathophysiology and risk of residual gastric volume with these drugs.
Original abstract (PubMed)
PURPOSE OF REVIEW: Glucagon-1 receptor agonists (GLP-1A) delay gastric emptying, which has raised concerns about heightened risk of increased residual gastric volume (RGV) despite appropriate fasting measures. RGV could increase risk of pulmonary aspiration during sedated procedures like upper endoscopy. The purpose of this review is to summarize literature on pathophysiology of delayed gastric emptying, and to highlight recent publications on risk of RGV and preventive strategies. RECENT FINDINGS: GLP-1A delay gastric emptying via vagally mediated pathways; with long-term use this delay in gastric emptying is attenuated. GLP-1A significantly increases risk of RGV. Holding a dose of GLP-1A or continuing the medication with 24 h of clear liquids beforehand are both effective strategies. There is a trend towards greater effectiveness with the latter approach. In experienced hands, point of care ultrasound (POCUS) is highly accurate at identifying RGV before sedation. SUMMARY: Recent studies have considerably enhanced our understanding of the pathophysiology and risk of RGV with GLP1A.
-
Bariatric Surgery, Medical Weight Loss, and the Upper Aerodigestive Tract.
AI summary of the abstract, unverified
- This review examines how bariatric surgery and medical weight-loss therapies affect the upper aerodigestive tract, covering mechanical, metabolic, inflammatory, and gastrointestinal effects.
- Evidence is strongest for obstructive sleep apnea, where substantial weight reduction improves severity but does not reliably lead to remission.
- Emerging data suggest possible benefits for chronic rhinosinusitis and some voice outcomes, alongside risks including reflux, chronic cough, delayed gastric emptying, and patulous Eustachian tube dysfunction.
- The authors advise otolaryngologists to account for weight-loss method, magnitude, rate, and durability in evaluation, counseling, and perioperative planning.
Original abstract (PubMed)
Obesity and intentional weight loss increasingly influence otolaryngologic disease through mechanical, metabolic, inflammatory, gastrointestinal, and regional soft-tissue effects. This review examines how bariatric surgery and contemporary medical weight-loss therapies affect the upper aerodigestive tract. Evidence is strongest for obstructive sleep apnea, in which substantial weight reduction improves disease severity but does not ensure remission. Emerging data suggest potential benefits for chronic rhinosinusitis and selected voice outcomes, alongside risks such as procedure-specific reflux, chronic cough, delayed gastric emptying, nutritional complications, and patulous Eustachian tube dysfunction. Otolaryngologists should incorporate the weight-loss method, magnitude, rate, and durability into evaluation, counseling, and perioperative planning.
-
Perioperative Safety Considerations and Surgical Outcomes Associated With GLP-1-Based Therapies: A Systematic Review.
AI summary of the abstract, unverified
- This PRISMA-guided, PROSPERO-registered systematic review included 16 studies: seven observational studies and nine case reports or case series in adults undergoing sedation or general anesthesia.
- The review examined perioperative gastric physiology and safety outcomes in patients taking GLP-1 receptor agonists, with semaglutide singled out in the observational data.
- Observational studies linked GLP-1 RA use to more residual gastric contents or delayed emptying despite standard fasting, while clinically apparent aspiration was uncommon and mainly described in case reports.
- Larger observational studies showed no clear increase in aspiration or broader complications, and retained gastric contents changed anesthetic plans or postponed elective cases in several reports.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for the management of type 2 diabetes mellitus and obesity. Their effects on gastric emptying have raised concerns in the perioperative setting, where standard fasting protocols are used to reduce aspiration risk. However, the clinical significance of altered gastric physiology and its implications for perioperative management remain uncertain. A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO) (registration number: CRD420261289189). A comprehensive literature search identified studies evaluating perioperative gastric physiology and procedural safety outcomes associated with GLP-1 RA use in adults undergoing procedures requiring sedation or general anesthesia. Outcomes included delayed gastric emptying, residual gastric contents, aspiration or regurgitation events, and perioperative management adaptations. Sixteen studies met the inclusion criteria, comprising seven observational studies and nine case reports or case series. Observational evidence demonstrated an association between GLP-1 RA use, particularly semaglutide, and increased residual gastric contents or delayed gastric emptying despite adherence to standard fasting protocols. These findings were identified primarily through gastric ultrasound and endoscopic assessment. In contrast, clinically apparent aspiration or regurgitation events were uncommon and were reported predominantly in case-based literature. Larger observational studies did not demonstrate a clear increase in aspiration or broader perioperative complications. Identification of retained gastric contents also influenced clinical management in several reports, resulting in changes to anesthetic planning, additional gastric assessment, or postponement of elective procedures. GLP-1 RA therapy is associated with alterations in gastric physiology that may challenge the assumptions underlying standard preoperative fasting protocols. Although increased residual gastric contents are consistently reported, current evidence does not establish a corresponding increase in clinically significant aspiration events. Individualized preoperative risk assessment, including consideration of medication exposure and selective use of gastric ultrasound, may assist perioperative decision-making. Further prospective studies are needed to quantify aspiration risk and establish evidence-based perioperative management strategies.
-
Molecular insights into GLP-1 receptor agonists and emerging metabolic-inflammatory targets in hidradenitis suppurativa.
AI summary of the abstract, unverified
- This narrative review covers metabolic-inflammatory pathways in hidradenitis suppurativa, including insulin/IGF-1 signaling, mTORC1 activation, adipokines, and gut-skin interactions.
- It evaluates evidence on GLP-1 receptor agonists, dual incretin agonists, and other metabolic interventions such as metformin in HS.
- The authors judge GLP-1 receptor agonists a possible adjunctive therapy for selected patients with HS and obesity or metabolic syndrome, but the abstract reports no quantitative results.
- They note that the existing evidence is mainly observational and confounded by concomitant therapies, so randomized trials with dermatologic and metabolic endpoints are needed.
Original abstract (PubMed)
INTRODUCTION: Hidradenitis suppurativa (HS) is increasingly recognized as a systemic immunometabolic disease associated with obesity, insulin resistance, and metabolic syndrome (MetS). A metabolically unhealthy lean phenotype indicates that metabolic dysfunction and chronic low-grade inflammation may occur independently of increased body mass index (BMI) in patients with HS. Reduced effectiveness of biologic therapies in patients with obesity further supports targeting the upstream metabolic drivers of inflammation. AREAS COVERED: This review outlines metabolic-inflammatory pathways proposed to contribute to HS, including insulin/insulin-like growth factor 1 (IGF-1) signaling, mechanistic target of rapamycin complex 1 (mTORC1) overactivation, adipokine dysregulation, and gut-skin interactions. Building on this framework, this review evaluates evidence on glucagon-like peptide-1 receptor agonists (GLP-1RAs), dual incretin agonists, and other metabolic interventions, including metformin is evaluated. EXPERT OPINION: GLP-1RAs may serve as adjunctive metabolic therapies for selected patients with HS and obesity or MetS. By promoting weight loss and metabolic improvement, they may reduce systemic inflammation, perioperative risk, and improve responses to weight-based biologics. However, current evidence remains mainly observational and is confounded by concomitant therapies. Randomized controlled trials using well-defined dermatological and metabolic endpoints are needed before routine implementation.
-
GLP-1 receptor agonists and weight-loss strategies for individuals with obesity and hip or knee osteoarthritis: a scoping review.
AI summary of the abstract, unverified
- This PRISMA-ScR scoping review of 199 studies (2010 to August 2025) mapped weight-loss strategies in adults with obesity and hip or knee osteoarthritis.
- Of the included studies, 36 (18.1%) directly assessed GLP-1 receptor agonists, and only 14 of those reported original data.
- Most GLP-1 studies (29/36) were published in 2024–2025, and 19/36 were level 5 evidence; knee data showed weight loss and pain/function gains, while hip data were sparse.
- The authors call GLP-1 receptor agonists a promising adjunct and advise using them within supervised, multimodal musculoskeletal care rather than as standalone weight-loss agents.
Original abstract (PubMed)
OBJECTIVE: To map current strategies for weight loss in hip and knee osteoarthritis (OA), with emphasis on the emerging role of glucagon-like peptide-1 receptor agonists (GLP-1-RAs) as tools in achieving weight loss and impacting symptoms, disease progression and perioperative outcomes in individuals with obesity. DESIGN: Scoping review conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) framework and methodological guidance from the Joanna Briggs Institute and Arksey and O'Malley. DATA SOURCES: PubMed, Web of Science, Directory of Open Access Journals, Scopus, ProQuest Central (1 January 2010 to 18 August 2025). ELIGIBILITY CRITERIA: Included studies focused on adults (≥18 years) with obesity and hip or knee OA, examined weight-loss strategies (nutritional, physical activity, surgical or pharmacological) including GLP-1-RAs. RESULTS: Of 199 included studies, 36 (18.1%) directly assessed GLP-1-RAs and of these, 14/36 (38.9%) reported original data. Evidence was heavily skewed towards knee OA, with limited hip-specific data. Descriptive analysis revealed a narrow geographical distribution of studies and a rapidly increasing focus on GLP-1-RAs; most studies involving GLP-1-RAs (29/36, 80.6%) were published between 2024 and 2025 and were of a low level of evidence (19/36, 52.8% level 5). Randomised and cohort data in knee OA indicate that GLP-1-RAs are associated with substantial weight loss, with accompanying improvements in pain/function and reduced progression to arthroplasty. In contrast, evidence in hip OA is sparse with weaker associations. CONCLUSION: GLP-1-RAs represent a promising adjunct for managing individuals with OA complicated by obesity. Until further evidence emerges, GLP-1-RAs should be integrated into supervised, multimodal musculoskeletal care rather than used as standalone weight-loss agents.
-
GLP-1 receptor agonists in elective spine surgery: a systematic review of fusion outcomes, perioperative safety, and procedure-specific risk.
AI summary of the abstract, unverified
- This systematic review qualitatively synthesized 23 studies, mostly retrospective cohorts and propensity-matched database analyses, in adults undergoing elective spine surgery.
- The exposure was documented preoperative or perioperative GLP-1 receptor agonist use, assessed against fusion, infection, readmission, complications, and length of stay.
- Lumbar fusion studies generally reported favorable or neutral associations, though some TLIF cohorts reported adverse ones, while cervical findings varied by surgical approach.
- No included study reported postoperative pancreatitis, and the authors stress that the findings are associations and that perioperative management should be individualized.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used in patients with obesity and type 2 diabetes mellitus undergoing elective spine surgery. Although these agents may improve metabolic risk profiles, their associations with spinal fusion, perioperative complications, and procedure-specific outcomes remain incompletely defined. METHODS: We conducted a systematic review and qualitative synthesis of comparative clinical studies evaluating adults undergoing spine surgery with documented preoperative or perioperative GLP-1 RA exposure. Eligible studies assessed fusion-related outcomes, perioperative medical complications, surgical site infection, readmission, length of stay, healthcare utilization or costs, and musculoskeletal outcomes. The review was conducted in accordance with PRISMA 2020 principles, with eligibility criteria defined using a PICOS framework. RESULTS: Twenty-three studies were included, consisting predominantly of retrospective cohort studies and propensity-matched database analyses. Lumbar fusion studies generally reported favorable or neutral associations between GLP-1 RA exposure and pseudarthrosis, infection, readmission, and healthcare utilization, although some transforaminal lumbar interbody fusion cohorts reported adverse associations. Cervical fusion outcomes were more heterogeneous and appeared to vary by surgical approach. Anterior cervical fusion studies generally reported neutral or favorable outcomes, whereas posterior cervical fusion studies yielded conflicting findings. Gastrointestinal safety data were sparse, no included study reported postoperative pancreatitis, and preoperative treatment duration and longitudinal BMI or weight change were incompletely characterized. CONCLUSIONS: Current evidence suggests that GLP-1 RA exposure is associated with procedure-specific differences in outcomes after elective spine surgery. Because the available evidence is predominantly observational, these findings should be interpreted as associations rather than evidence of direct causal benefit or harm. Perioperative GLP-1 RA management should be individualized according to surgical procedure, metabolic status, gastrointestinal symptoms, renal and hydration risk, and nutritional or sarcopenia-related vulnerability.
-
Medication Safety and Perioperative Risk Management of GLP-1 Receptor Agonists: A Pharmacist-Led Framework for Individualized Care.
AI summary of the abstract, unverified
- This narrative review summarizes evidence on GLP-1 receptor agonist delayed gastric emptying and proposes a pharmacist-led perioperative risk framework.
- GLP-1 receptor agonists may leave residual gastric contents despite standard fasting, yet outcome studies have not consistently shown more aspiration pneumonia.
- These aspiration findings are limited by rare events, mostly retrospective designs, residual confounding, and inconsistent definitions of residual gastric contents.
- The proposed pathway covers medication verification, symptom screening, risk phenotyping, selective gastric ultrasound, and restart planning, and the authors call for prospective testing.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for type 2 diabetes, obesity, and broader cardiometabolic, cardiorenal, and metabolic liver disease indications, creating new challenges for perioperative medication safety. This review summarizes current evidence on GLP-1RA-associated delayed gastric emptying and proposes a structured pharmacist-led framework for individualized perioperative risk management. GLP-1RAs may increase the likelihood of residual gastric contents during anesthesia or procedural sedation despite adherence to standard fasting recommendations. Perioperative outcome studies have not consistently shown an increased risk of aspiration pneumonia; however, these findings should be interpreted in light of the low incidence of aspiration-related events, the predominance of retrospective study designs, residual confounding, and heterogeneous definitions of residual gastric contents. We review mechanisms of delayed gastric emptying, treatment- and patient-related risk modifiers, perioperative clinical evidence, areas of agreement and divergence among major guidance statements, gastric ultrasonography as a selective risk-mitigation tool, and medication-safety issues beyond aspiration, including oral drug absorption and postoperative resumption. Because perioperative GLP-1RA decisions require accurate medication history, last-dose verification, symptom assessment, evaluation of glycemic consequences of drug interruption, coordination with anesthesia and surgical teams, and safe postoperative restart planning, pharmacists are well positioned to support this process. The proposed pharmacist-led pathway provides a structured approach to GLP-1RA medication verification, gastrointestinal symptom screening, risk phenotyping, multidisciplinary escalation, day-of-surgery reassessment, postoperative restart planning, patient education, and documentation. Perioperative GLP-1RA management should not rely on routine discontinuation alone, but should integrate treatment phase, dose escalation, gastrointestinal symptoms, comorbid motility disorders, procedural urgency, anesthetic risk, oral medication considerations, and the metabolic consequences of withholding therapy. This pathway represents a structured implementation framework informed by current evidence and guidance; prospective evaluation in real-world perioperative settings is needed.
-
Obesity and Upper Aerodigestive Dysfunction: Voice, Swallowing, Reflux, and Airway Considerations in Laryngology.
AI summary of the abstract, unverified
- This is a narrative review article in Otolaryngologic Clinics of North America, with no original study population or sample size reported.
- It describes how obesity may alter respiratory mechanics, upper airway stability, reflux, esophageal clearance, gastric emptying, and systemic inflammation.
- It covers voice, swallowing, reflux, airway mechanics, and perioperative and postoperative risks, aimed at laryngologists and general otolaryngologists.
Original abstract (PubMed)
Obesity alters upper aerodigestive physiology through changes in respiratory mechanics, upper airway stability, reflux burden, esophageal clearance, gastric emptying, and systemic inflammation. These changes may contribute to a myriad of voice, swallowing, and airway pathologies. This article examines the relationship between obesity and upper aerodigestive tract disorders, focusing on voice, swallowing, reflux, airway mechanics, perioperative/postoperative risks, and management relevant to laryngologists and comprehensive otolaryngologists alike.
-
An Updated Review of Glucagon-Like Peptide-1 Receptor Agonists: Perioperative Implications, Guidance Statements, and Current Literature.
AI summary of the abstract, unverified
- This is a narrative review of glucagon-like peptide-1 receptor (GLP-1) agonists in patients undergoing surgery.
- It covers the history and mechanism of action of these drugs, then recent evidence and perioperative management strategies.
- The abstract highlights delayed gastric emptying and the resulting aspiration risk during anesthesia as the central concern, but reports no specific findings or numbers.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor (GLP-1) agonist medications are becoming a commonly prescribed medication for patients undergoing surgical procedures. Perioperative management of this medication has become an important topic due to the known delayed gastric emptying leading to the potential for retained gastric contents elevating the risk for aspiration during anesthesia. This update will briefly review the history and mechanism of action of these medications. We will then pivot to discuss recent evidence and best practice strategies in managing perioperative patients on GLP-1 therapy.
-
Beyond Weight Loss: A Comprehensive Review of Integrated Pharmacotherapy and Metabolic Bariatric Surgery in Endometrial Cancer Care.
AI summary of the abstract, unverified
- This is a narrative review following SANRA criteria, synthesizing evidence on metabolic interventions in women with severe obesity and endometrial cancer, with no pooled patient numbers reported.
- The interventions reviewed are minimally invasive metabolic/bariatric surgery, including combined surgery with hysterectomy, and GLP-1 receptor agonists.
- The review finds combined bariatric surgery and hysterectomy appears feasible for selected patients, and GLP-1RAs may affect obesity-related and tumor-associated pathways, but direct antitumor benefit is not established.
- The authors conclude obesity is modifiable, weight reduction lowers endometrial cancer risk, but cancer-specific survival benefit is undemonstrated and prospective studies are needed before guideline inclusion.
Original abstract (PubMed)
Backgroundand Objectives: Endometrial cancer ranks among the most prevalent gynecologic malignancies in high-income countries, with increasing incidence and mortality driven by the global obesity epidemic. Evidence suggests that women with early-stage disease face a greater risk of death from obesity-related comorbidities than from cancer recurrence and that weight reduction is associated with improvements in quality of life and in the long-term burden of obesity-related morbidity and mortality. Minimally invasive (MIS) metabolic/bariatric surgery is the most effective treatment for achieving significant, sustained weight loss and comorbidities resolution/improvement. Advances in MIS (laparoscopic, robotic, and endoscopic) techniques have reduced perioperative morbidity and mortality. Novel pharmacotherapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), have recently received regulatory approval for weight management and ongoing studies are investigating their therapeutic impact on endometrial carcinogenesis and tumor biology. This review synthesizes and critically appraises evidence on metabolic interventions, including innovative bariatric techniques and pharmacologic agents, with the aim of informing their integration into multidisciplinary, risk-adapted management strategies for patients with severe obesity and endometrial cancer. Materials and Methods: A comprehensive review was conducted in accordance with SANRA (Scale for the Assessment of Narrative Review Articles) criteria. Results: Emerging evidence indicates that MIS metabolic/bariatric surgery combined with hysterectomy is feasible and may be integrated into the multidisciplinary management of selected patients with severe obesity and endometrial hyperplasia or carcinoma. GLP-1RAs may modulate both the obesogenic systemic milieu and selected tumor-associated pathways, although definitive clinical evidence of direct antitumor effect and oncologic benefit in endometrial cancer has not been established. Conclusions: Obesity is a modifiable risk factor for endometrial cancer. Metabolic/bariatric interventions represent a promising component of the comprehensive, patient-centered management of this disease. Prospective studies are essential to clarify the association between these interventions and longitudinal oncologic outcomes, the feasibility and potential benefits of combined approaches, and their differential impact according to the molecular classification of endometrial cancers. Although weight reduction is associated with a lower risk of endometrial cancer, a direct improvement in cancer-specific survival has not yet been demonstrated; weight-loss management therefore represents a promising component of care in the severely obese population, and its incorporation into formal guidelines requires confirmation in prospective studies.
-
Perioperative Optimization Strategies in Major Genitourinary Cancer Surgery.
AI summary of the abstract, unverified
- This narrative literature review drew on PubMed-indexed trials, observational studies, systematic reviews, and guidelines on perioperative optimization for genitourinary cancer surgery.
- The review covered enhanced recovery protocols, nutrition, exercise prehabilitation, smoking cessation, GLP-1 receptor agonists, and gut microbiome modulation.
- The abstract reports that enhanced recovery protocols reduce acute complications and shorten length of stay, and that smoking cessation improved wound healing and lowered pulmonary and infectious complications.
- Evidence for GLP-1 receptor agonists and microbiome-targeted interventions is described as emerging with limited clinical data, and the authors call for prospective studies.
Original abstract (PubMed)
OBJECTIVE: To evaluate current and emerging perioperative optimization strategies in genitourinary surgery and assess their potential to improve surgical outcomes, particularly in patients with modifiable risk factors. METHODS: A literature review was conducted using PubMed databases examining perioperative interventions relevant to patients undergoing surgery for genitourinary cancers. Areas of focus included enhanced recovery after surgery protocols, nutritional optimization, exercise prehabilitation, smoking cessation, glucagon-like peptide-1 receptor agonists, and gut microbiome modulation. Evidence from clinical trials, observational studies, systematic reviews, and current clinical guidelines was reviewed and synthesized. RESULTS: Current evidence supports the use of enhanced recovery after surgery protocols to reduce acute complications, shorten length of stay and decrease recovery time. Nutritional optimization and exercise prehabilitation demonstrated improved functional and metabolic capacity. Smoking cessation improved wound healing and decreased pulmonary and infectious complications. Emerging evidence suggests GLP-1 RAs offer metabolic benefits, and microbiome-targeted interventions may improve postoperative recovery through gut microbiome diversity preservation, although clinical data remains limited. CONCLUSIONS: Perioperative strategies demonstrate promising potential to improve outcomes in patients undergoing genitourinary surgeries by addressing modifiable risk factors. Further prospective studies are needed to guide clinical implementation.
-
Do glucagon-like peptide-1 receptor agonists influence cervical fusion outcomes? A systematic review and meta-analysis.
AI summary of the abstract, unverified
- Systematic review and meta-analysis of six propensity score-matched retrospective cohort studies, including 17,310 adults undergoing cervical fusion.
- Compared perioperative GLP-1 receptor agonist use against non-use in patients undergoing cervical fusion.
- No significant association was found for pseudarthrosis (OR 0.98, 95% CI 0.33-2.89), dysphagia (OR 0.89, 95% CI 0.38-2.05), readmission (OR 0.67, 95% CI 0.39-1.17), or device failure (OR 0.83, 95% CI 0.44-1.56).
- The authors conclude GLP-1RA use was not consistently linked to worse outcomes after cervical fusion and call for prospective, procedure-specific studies.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in patients with obesity and type 2 diabetes, but their procedure-specific effects in cervical fusion remain unclear. METHODS: A systematic review and meta-analysis following PRISMA 2020 and MOOSE, prospectively registered in PROSPERO, searched PubMed, Embase, and Web of Science through April 28, 2026. Comparative studies evaluating perioperative GLP-1RA use in adults undergoing cervical fusion were included. Two reviewers independently screened studies, extracted data, and assessed risk of bias. Random-effects meta-analyses were performed in Review Manager Web (RevMan Web). Certainty of evidence was assessed using the GRADE approach for clinically important outcomes. RESULTS: Six propensity score-matched retrospective cohort studies involving 17,310 patients were included. In the primary analyses, GLP-1RA use was not associated with significant differences in pseudarthrosis (odds ratio [OR] 0.98, 95% confidence interval [CI] 0.33-2.89; p = .96), dysphagia (OR 0.89, 95% CI 0.38-2.05; p = .68), hospital readmission (OR 0.67, 95% CI 0.39-1.17; p = .12), or device failure (OR 0.83, 95% CI 0.44-1.56; p = .41). Secondary outcomes were also not significantly different between groups. CONCLUSIONS: Perioperative GLP-1RA use was not associated with a consistent pattern of worse postoperative outcomes after cervical fusion. Prospective, procedure-specific studies with standardized exposure and outcome definitions are needed.
-
Perioperative management of GLP-1 receptor agonists: a structured narrative review with considerations relevant to neurosurgical patients.
AI summary of the abstract, unverified
- Structured narrative review of perioperative studies, gastric ultrasound reports, meta-analyses, and society guidance on GLP-1 receptor agonist use in anesthesia and surgery.
- The review focuses on neurosurgical factors such as urgent surgery, prone positioning, posterior fossa pathology, and baseline bulbar dysfunction.
- Evidence links GLP-1 receptor agonists with more gastric retention, especially during dose escalation, while population studies and meta-analyses show no rise in aspiration.
- The authors propose a risk-level-based perioperative approach but present it as expert extrapolation, not evidence-based neurosurgery guidelines, given limited neurosurgery-specific data.
Original abstract (PubMed)
PURPOSE: The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is increasing in the treatment of obesity and type 2 diabetes mellitus. Some patients taking these medications undergo cranial or spinal surgical procedures. Delayed gastric emptying is a key mechanism of action for these medications. Despite the standard preoperative fasting period, there is a risk of residual gastric contents remaining in the perioperative period. Since neurosurgical patients face a risk of postoperative complications such as aspiration, delayed extubation, and postoperative nausea and vomiting, there is a need for a clinically focused review. METHODS: We performed a structured narrative review of perioperative studies, gastric ultrasound reports, meta-analyses, and professional society guidance addressing GLP-1RA use in anesthesia, surgery, and procedural sedation. Evidence was qualitatively synthesized with particular attention to procedural and physiologic factors relevant to neurosurgical practice, including urgent surgery, prone positioning, posterior fossa pathology, and baseline bulbar dysfunction. RESULTS: Current evidence consistently links the use of GLP-1 receptor agonists (GLP-1RAs) with an increased likelihood of gastric retention, particularly during dose escalation and in patients with active gastrointestinal symptoms. However, population-level studies and meta-analyses have not shown an increase in pulmonary aspiration rates. Although aspiration is not very common in neurosurgical patients, when it does occur, its consequences may be more severe than expected. Direct evidence specific to neurosurgery in the perioperative setting remains limited. CONCLUSION: A practical perioperative management approach structured according to risk level can assist in assessing the patient's symptoms and stage of treatment. It can also ensure that procedure-specific risk factors are taken into account, appropriate risk-reduction measures are selected, and the resumption of medication in the postoperative period is individualized. Due to the limited evidence specific to neurosurgery, these assessments should not be interpreted as evidence-based neurosurgery guidelines. They should instead be viewed as expert-driven extrapolations adapted from the broader perioperative literature to neurosurgical practice.
-
Korean consensus-based recommendations for preanesthetic gastric ultrasound and anesthetic considerations for GLP-1 receptor agonist-based therapy: a consensus statement from Clinical Practice Guideline Committee of the Korean Society of Anesthesiologists.
AI summary of the abstract, unverified
- This is a Korean Society of Anesthesiologists consensus statement built from expert discussion and literature review, not a primary study with patient data.
- It covers when to use preanesthetic gastric ultrasound and how to interpret and act on findings, including GLP-1 receptor agonist therapy.
- For GLP-1 RA patients, it favors continuing the drug in most cases after individualized risk assessment, and it suggests considering a 24-hour clear liquid diet.
- The authors state the evidence is insufficient for evidence-graded guidelines and call for prospective outcome-based studies to refine these recommendations.
Original abstract (PubMed)
Pulmonary aspiration during anesthesia remains an uncommon but clinically significant perioperative complication associated with substantial morbidity and mortality. Although contemporary fasting guidelines recommend minimum fasting intervals to reduce aspiration risk, adherence does not guarantee an empty stomach, particularly in patients with delayed gastric emptying or those receiving medications that impair gastrointestinal motility, such as glucagon-like peptide-1 receptor agonist (GLP-1 RA)-based therapies. Preanesthetic gastric ultrasound has emerged as a practical point-of-care modality for the qualitative and quantitative assessment of gastric content and volume, enabling individualized aspiration risk stratification in selected patients. However, the current evidence base remains insufficient to formally support evidence-graded clinical practice guidelines. The consensus-based recommendations presented in this guideline were developed through expert discussion and review of the available literature, in which robust evidence is lacking. They provide practical guidance on the indications for preanesthetic gastric ultrasound, core examination principles and interpretation, integration of ultrasound findings into perioperative decision-making, management when gastric ultrasound is not feasible, and anesthetic strategies for patients with a full stomach. Special recommendations are included for patients receiving GLP-1 RA-based therapies, emphasizing the continuation of these medications in most patients with individualized risk assessment, consideration of a 24-h clear liquid diet, and the use of gastric ultrasound when delayed gastric emptying is suspected. Preanesthetic gastric ultrasound provides a practical bedside method for assessing gastric content and estimating aspiration risk in patients undergoing anesthesia. These recommendations are intended to support, not replace, clinical judgment and should be refined through future prospective outcome-based studies.
PubMed 42529794 Publisher (DOI) PubMed types: Consensus Statement, Journal Article, Review, Research Support, Non-U.S. Gov't -
Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists.
AI summary of the abstract, unverified
- This is a narrative review, not a primary study, covering GLP-1 receptor agonist history, mechanism, and approved agents.
- It compares weight-loss effects across available GLP-1 receptor agonists and discusses their use alongside bariatric surgery.
- The review addresses perioperative considerations for surgical patients taking these drugs and proposes suggested recommendations.
- The abstract reports no quantitative data, so the recommendations' basis and specifics must be checked in the full text.
Original abstract (PubMed)
This article begins by providing historical insight into the discovery, development, and use of glucagon-like peptide-1 receptor (GLP-1R) agonist medications in the treatment of type 2 diabetes and obesity. Next, the mechanism of action and impacts of GLP-1R agonists are discussed, along with an overview of the Food and Drug Administration-approved GLP-1R agonists currently on the market. Comparison in effects on weight loss of the available GLP-1R agonists is briefly discussed, along with its use in the context of bariatric surgery. Finally, perioperative considerations for surgical patients using GLP-1R agonists are reviewed along with suggested recommendations.
-
GLP-1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri-Procedural Guidance.
AI summary of the abstract, unverified
- Narrative review synthesizing pharmacological, scintigraphic, observational, and consensus evidence on GLP-1 receptor agonists, gastric emptying, and endoscopy.
- Focuses on GLP-1RA exposure in patients undergoing endoscopy and its effect on gastric motility and retained gastric contents.
- Retained gastric contents and procedural disruptions are more frequent with GLP-1RAs in upper GI endoscopy, while reported aspiration rates are about 0.01%-0.05% for colonoscopy and under 0.3% for upper GI procedures.
- The authors favor continuing GLP-1RAs with dietary modification, risk assessment, selective gastric POCUS, and team communication rather than routine cessation, and note emerging prospective data on pre-procedural clear liquid diets.
Original abstract (PubMed)
The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction-associated steatotic liver disease (MASLD) has led to a higher use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) among patients undergoing gastrointestinal endoscopy. Although GLP-1RAs provide significant metabolic, cardiovascular, and hepatic benefits, their tendency to slow gastric emptying has raised concerns about retained gastric contents (RGC), procedural complications, and a greater risk of pulmonary aspiration during sedation or anesthesia. This review offers a translational narrative synthesis of mechanistic, physiological, and clinical evidence connecting GLP-1RA therapy to changes in gastric motility and peri-endoscopic outcomes. Data from pharmacological studies, scintigraphic evaluations, large observational cohorts, and international consensus statements are combined to guide physiology-based procedural decisions. Evidence consistently indicates that GLP-1RA exposure is associated with a higher incidence of RGC and more frequent procedural disruptions during upper gastrointestinal endoscopy. However, it remains uncertain whether RGC leads to clinically significant aspiration. Consistent with this, real-world data reveal no increase in aspiration pneumonia among GLP-1RA users undergoing colonoscopy, with reported aspiration rates of approximately 0.01%-0.05%. Likewise, during upper gastrointestinal endoscopy, only a small absolute rise in aspiration-related events has been observed, involving fewer than 0.3% of procedures. Current guidelines favor continuing GLP-1RA therapy alongside dietary modification, structured risk assessment, selective gastric point-of-care ultrasound (POCUS), and multidisciplinary communication, rather than routine cessation. Emerging prospective evidence indicates that implementing a pre-procedural clear liquid diet, with individualized timing of weekly agents, may reduce the risk of clinically significant RGC, complementing existing dietary preparation strategies.
-
Glucagon-like peptide-1 receptor agonists as a metabolic optimization strategy in surgical prehabilitation: a translational perspective.
AI summary of the abstract, unverified
- This narrative translational review explores whether GLP-1 receptor agonists could serve as a pharmacological adjunct to multimodal prehabilitation before major abdominal surgery.
- It covers the biological rationale, sarcopenic obesity, implications for oncologic surgery and neoadjuvant therapy, and emerging data from bariatric and metabolic surgery.
- It highlights perioperative safety concerns, particularly delayed gastric emptying and aspiration risk, along with current anesthetic guidance.
- The authors state there is currently no direct evidence for this use and propose prospective studies to test feasibility, safety, and clinically meaningful outcomes.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide and tirzepatide, are increasingly prescribed for obesity and type 2 diabetes and have demonstrated substantial and rapid weight loss in large randomized trials. At the same time, prehabilitation before major abdominal surgery has become an established perioperative strategy to improve postoperative outcomes. This review explores the potential role of GLP-1RAs as a pharmacological adjunct in multimodal surgical prehabilitation. We discuss the biological rationale for metabolic optimization, the relevance of sarcopenic obesity, potential implications for oncological surgery and neoadjuvant therapy, and emerging data from bariatric and metabolic surgery. We also highlight important perioperative safety considerations, particularly delayed gastric emptying and aspiration risk, and current anesthetic guidance. Although integration of GLP-1RAs into prehabilitation pathways is biologically plausible and clinically attractive, there is currently no direct evidence supporting their use in this setting. We propose that GLP-1RAs represent a promising and testable strategy for metabolic optimization in surgical patients. Prospective studies are required to evaluate feasibility, safety, and impact on clinically meaningful outcomes. This framework is hypothesis-generating and aims to inform future translational research at the interface of metabolic medicine and perioperative care.
-
Impact of Obesity, Sarcopenia, and Nutritional Status on Spine Surgery Patients.
AI summary of the abstract, unverified
- This narrative review covers obesity phenotypes, sarcopenic obesity, and nutritional deficiency in spine surgery patients, with no pooled sample or effect sizes reported.
- The authors argue that body mass index alone misses fat distribution, muscle quality, and nutritional status, all of which affect perioperative risk.
- Central adiposity and sarcopenic obesity are described as independent predictors of wound complications, mechanical failure, and delayed recovery, and nutritional deficiencies may impair fusion.
- The review proposes a preoperative optimization framework using dietary counseling, resistance prehabilitation, and multidisciplinary care, and calls GLP-1 receptor agonists a promising option.
Original abstract (PubMed)
Obesity, sarcopenia, and malnutrition are increasingly recognized as key determinants of outcomes in spine surgery. Reliance on body mass index alone does not capture variations in fat distribution, muscle quality, or nutritional status, each of which affects perioperative risk. Central adiposity and sarcopenic obesity are independent predictors of wound complications, mechanical failure, and delayed recovery. Nutritional deficiencies in obese and postbariatric patients, including low levels of vitamin D, iron, and protein, can further impair bone healing and fusion. Emerging evidence supports structured preoperative optimization through dietary counseling, resistance-based prehabilitation, and coordinated multidisciplinary management. Glucagon-like peptide-1 receptor agonists represent a promising pharmacologic option that improves metabolic control and facilitates weight reduction without the malabsorption associated with bariatric surgery. This review summarizes current understanding of obesity phenotypes, sarcopenic obesity, and nutritional deficiency in spine patients and presents a practical framework for preoperative optimization to reduce complications, enhance fusion rates, and improve long-term surgical outcomes.
-
Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology - Head and Neck Surgery: A Review.
AI summary of the abstract, unverified
- This is a review article covering how GLP-1 receptor agonists affect otolaryngology and head and neck surgery.
- Delayed gastric emptying raises perioperative aspiration concern, so anesthetic guidance on cessation and fasting matters for safety and scheduling.
- The review describes benefit for obstructive sleep apnea in patients with obesity, with possible relevance to sinusitis, olfaction, hearing loss, and facial appearance.
- Animal studies suggested thyroid cancer risk, but population studies are inconclusive and the authors call for long-term investigation of causality.
Original abstract (PubMed)
The number of patients taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) is increasing. Beyond diabetes and weight management, these medications have various effects within the head and neck with both beneficial and potentially adverse clinical implications. Delayed gastric emptying may contribute to reflux, chronic cough, and potential aspiration in the perioperative setting; as such, physicians should be aware of anesthetic guidelines (duration of pre-operative cessation, pre-operative fasting or liquid diet) to improve safety and avoid operative delay. GLP-1RAs have shown benefit in treating obstructive sleep apnea in those with obesity or overweight and may become increasingly relevant in multimodal treatment of sleep disorders. GLP-1 receptor signaling is involved in sinopulmonary inflammatory cascades and recent evidence suggests clinical implications for chronic sinusitis and olfactory disorders. Previously reported neuroprotective effects have led to investigation regarding potential benefit in neurotoxicity-associated hearing loss. Muscle atrophy with weight loss may contribute to a gaunt, aged appearance leading patients to seek facial rejuvenation, or to a patulous eustachian tube and changes in conductive hearing. Animal studies suggested an increased risk of thyroid cancer, but population studies have been inconclusive and will require long-term investigation to determine any causal relationship.
-
What obgyns need to know about GLP-1 receptor agonists.
AI summary of the abstract, unverified
- This narrative review synthesizes current evidence on GLP-1 and dual GLP-1/GIP receptor agonists for obstetric and gynecologic practice, with a focus on women's health.
- Phase 3 trials report 15-21% body weight reduction, with tirzepatide described as superior to semaglutide, and PCOS meta-analyses report improved insulin resistance, androgen levels, and ovulation rates.
- Manufacturer guidance advises backup contraception for 4 weeks after tirzepatide initiation or dose escalation, because the drug significantly delays gastric emptying.
- Early human cohort studies of inadvertent early pregnancy exposure report no increased risk of major congenital malformations, which the authors describe as preliminary reassurance.
Original abstract (PubMed)
PURPOSE OF REVIEW: Obstetricians and gynecologists increasingly encounter patients using glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide agonists. This review synthesizes evidence on these agents, focusing on their relevance in women's health. RECENT FINDINGS: GLP-1 receptor agonists and dual agonists achieve 15-21% body weight reduction in phase 3 trials, with tirzepatide demonstrating superior efficacy compared to semaglutide. Key populations of interest include patients with polycystic ovary syndrome (PCOS), pregnant patients, and those undergoing gynecologic surgery. In women with PCOS, meta-analyses confirm improvements in insulin resistance, androgen levels, and ovulation rates. Tirzepatide significantly delays gastric emptying, prompting manufacturer guidance to use backup contraception for 4 weeks after initiation or dose escalation. Emerging human cohort studies of inadvertent early pregnancy exposure report no increased risk of major congenital malformations, providing preliminary reassurance despite animal teratogenicity data. Perioperative guidance has evolved from blanket discontinuation to individualized, risk-stratified approaches. SUMMARY: GLP-1 receptor agonists offer benefits across the lifespan, with promising applications in PCOS and preconception optimization. Reproductive-aged women need counseling regarding contraception and preconception discontinuation. Knowledge gaps include the need for pregnancy registries. Obstetrician-gynecologists will increasingly encounter these therapies and must navigate evolving evidence regarding their safety, efficacy, and clinical implications.
-
Perioperative Nutritional Optimization in Total Joint Arthroplasty: From Screening to Supplementation.
AI summary of the abstract, unverified
- This targeted narrative review searched PubMed/MEDLINE and Google Scholar for nutritional optimization strategies in total hip and total knee arthroplasty patients.
- It covers biochemical screening, vitamin D, vitamin C, magnesium, micronized purified flavonoid fraction, essential amino acids, and carbohydrate loading.
- Vitamin D deficiency affects 13 to 63% of TJA patients and is consistently associated with more complications, poorer function, and higher infection risk.
- The authors conclude that perioperative nutritional optimization is safe and evidence-supported, and that integrating it into prehabilitation may reduce complications.
Original abstract (PubMed)
BACKGROUND: Malnutrition and suboptimal nutrient status are increasingly recognized as modifiable risk factors influencing outcomes after total joint arthroplasty (TJA). Older adults and medically complex patients are particularly vulnerable to perioperative catabolism, impaired wound healing, and delayed functional recovery. This review synthesized current evidence on perioperative nutritional optimization, including biochemical screening, micronutrient correction, essential amino acid (EAA) supplementation, and adjunctive metabolic strategies, to support recovery in patients undergoing total hip arthroplasty and total knee arthroplasty. METHODS: A targeted narrative literature review was performed using PubMed/MEDLINE and Google Scholar databases. Search terms included combinations of "total joint arthroplasty," "total knee arthroplasty," "total hip arthroplasty," "malnutrition," "albumin," "vitamin D," "vitamin C," "essential amino acids," "HMB," "arginine," "glutamine," "bioflavonoids," "micronized purified flavonoid fraction," "carbohydrate loading," and "GLP-1 receptor agonists." Priority was given to randomized controlled trials, systematic reviews, meta-analyses, and large observational studies with direct relevance to arthroplasty populations. RESULTS: Vitamin D deficiency (13 to 63% of TJA patients) is consistently associated with increased complications, impaired functional scores, and higher infection risk, with favorable outcomes observed after targeted repletion. Vitamin C improves collagen synthesis, decreases inflammatory markers, reduces pain, and lowers the incidence of complex regional pain syndrome. Magnesium supports vitamin D activation, analgesia, and collagen stability. Bioflavonoids, particularly micronized purified flavonoid fraction, demonstrate high-quality evidence for reducing postoperative swelling and improving early motion after total knee arthroplasty. The use of EAA supplementation preserves quadriceps muscle mass, improves strength recovery, and accelerates return to activities of daily living. Carbohydrate loading mitigates postoperative insulin resistance, and glucagon-like peptide-1 receptor agonists offer metabolic benefits but require individualized perioperative management. CONCLUSIONS: Perioperative nutritional optimization, including vitamin D repletion, vitamin C, magnesium support, micronized purified flavonoid fraction therapy, and structured EAA supplementation, represents a safe, accessible, and evidence-supported strategy to enhance recovery after TJA. Integrating targeted nutrition into prehabilitation pathways may help reduce complications and support faster functional gains.
-
Nutritional Challenges in Post-Massive Weight Loss Body Contouring: Guidance for Plastic Surgeons on GLP-1 Agonists and Sleeve Gastrectomy.
AI summary of the abstract, unverified
- This narrative review addresses nutrition for patients with massive weight loss undergoing body contouring, focusing on sleeve gastrectomy and GLP-1 receptor agonist use.
- Sleeve gastrectomy carries fewer malabsorptive risks than gastric bypass but still predisposes patients to iron, vitamin B12, and protein deficiencies.
- GLP-1 receptor agonists such as semaglutide and tirzepatide suppress appetite and delay gastric emptying, which may further reduce protein and micronutrient intake.
- The authors recommend individualized protein timing, micronutrient correction, and supplementation, noting that many patients fall short of the 60 to 120 g/day protein guideline.
Original abstract (PubMed)
With obesity affecting more than 40% of US adults, bariatric surgery has become a cornerstone of obesity treatment, resulting in massive weight loss but also significant nutritional challenges. As demand for body contouring surgery after bariatric surgery increases, plastic surgeons must understand how evolving weight loss strategies, particularly the widespread use of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) and the shift to laparoscopic sleeve gastrectomy, affect nutritional status and wound healing. Laparoscopic sleeve gastrectomy presents fewer malabsorptive risks than Roux-en-Y gastric bypass, but still predisposes patients to deficiencies in iron, vitamin B12, and protein due to reduced intake and food intolerance. The rise of GLP-1 medications, such as semaglutide and tirzepatide, presents new considerations. These agents suppress appetite and delay gastric emptying, which can further reduce protein and micronutrient intake. For patients on GLP-1 RAs undergoing body contouring surgery, nutritional strategies must be tailored to ensure adequate perioperative protein and caloric intake, emphasizing timing, such as spacing protein throughout the day and increasing intake through small, more frequent meals. Protein deficiency, which impairs collagen production, angiogenesis, and immunity, is a key risk factor for poor wound healing. Despite guidelines recommending 60 to 120 g/day of protein, many patients fall short, particularly those losing weight on GLP-1 RAs. Perioperative nutritional optimization, including individualized protein timing plans, aggressive correction of micronutrient deficiencies, and supplementation strategies, is essential. This review provides comprehensive recommendations for plastic surgeons caring for patients with massive weight loss, including those using GLP-1 RAs, to optimize surgical outcomes and minimize complications.
Earlier evidence / dates not confirmed
Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.
- No matching papers in this section with the selected filters.
Ongoing registrations
From ClinicalTrials.govRegistrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.
No registered ongoing trials found.